Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years

NCT04027894 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT04027894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04027894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2024
Completion date
December 31, 2025
Enrollment
142 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

traveler's diarrhea